Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ramesh Chandra

Interventional Cardiology Fort Myers, FL Medical Doctor

NPI 1326318130 CMS profile 799553

13340 Metro Pkwy Ste 200, Fort Myers, FL 33966

Open in the dashboard

General payments

$6,749

194 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ramesh Chandra of Fort Myers, FL is reported in the CMS Open Payments database as having received $6,749 across 194 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 47th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $775 11
2024 General $2,079 21
2023 General $168 2
2022 General $204 5
2021 General $431 27
2020 General $419 27
2019 General $2,673 101

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ramesh Chandra
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Ramesh Chandra were reported at $775. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Ramesh Chandra Interventional Cardiology median Middle half National median
2019 $2,673 $1,097 $329–$3,048 $163
2020 $419 $473 $161–$1,480 $114
2021 $431 $677 $233–$1,827 $132
2022 $204 $978 $333–$2,724 $149
2023 $168 $1,136 $382–$2,986 $160
2024 $2,079 $1,181 $395–$3,326 $164
2025 $775 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $1,999 20 payments
  2. Medtronic Vascular, Inc. $1,005 14 payments
  3. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $521 27 payments
  4. Biocompatibles, Inc. $503 2 payments
  5. Novartis Pharmaceuticals Corporation $308 32 payments
  6. Janssen Pharmaceuticals, Inc $288 21 payments
  7. Abiomed $285 3 payments
  8. Boston Scientific Corporation $277 6 payments
  9. Medtronic, Inc. $222 3 payments
  10. Amgen Inc. $218 11 payments
  11. Other $1,123 55 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,380 183 payments
  2. Travel and Lodging $2,299 9 payments
  3. Education $70 2 payments
Products named General payments · program years 2019–2025
  1. OPTIS $1,905 15 payments
  2. Azure $783 7 payments
  3. EKOSONIC $536 4 payments
  4. LifeVest $521 27 payments
  5. ENTRESTO $308 32 payments
  6. XARELTO $288 21 payments
  7. Impella $268 2 payments
  8. Repatha $218 11 payments
  9. SYMPLICITY G3 $199 1 payment
  10. INSPIRE $158 1 payment
  11. Other $1,739 87 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

861

Median for Interventional Cardiology: 2,236

Drug cost

$182,781

Median for Interventional Cardiology: $380,412

Branded share of claims

31%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 82 $103,746
Xarelto Rivaroxaban Brand 25 $39,960
Repatha Sureclick Evolocumab Brand 16 $14,285
Brilinta Ticagrelor Brand 16 $13,463
Prasugrel Hcl Generic 24 $2,066
Ranolazine Er Ranolazine Brand 14 $1,704
Ezetimibe Generic 49 $1,352
Metoprolol Succinate Generic 67 $1,191
Clopidogrel Clopidogrel Bisulfate Brand 89 $901
Atorvastatin Calcium Generic 110 $882

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 72 billing codes

Paid by Medicare

$176,616

Medicare's payments for the services billed

Medicare patients

809

Average age 77

Services billed

2,298

375 women, 434 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 74%
Arthritis 57%
Heart failure 50%
Atrial fibrillation 49%
Chronic kidney disease 42%
Diabetes 41%
Depression 36%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

194 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record